252 related articles for article (PubMed ID: 25092699)
1. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.
Jabara CB; Hu F; Mollan KR; Williford SE; Menezes P; Yang Y; Eron JJ; Fried MW; Hudgens MG; Jones CD; Swanstrom R; Lemon SM
Antimicrob Agents Chemother; 2014 Oct; 58(10):6079-92. PubMed ID: 25092699
[TBL] [Abstract][Full Text] [Related]
2. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
3. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.
Ogishi M; Yotsuyanagi H; Tsutsumi T; Gatanaga H; Ode H; Sugiura W; Moriya K; Oka S; Kimura S; Koike K
PLoS One; 2015; 10(3):e0119145. PubMed ID: 25748426
[TBL] [Abstract][Full Text] [Related]
4. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.
Abdel-Hameed EA; Rouster SD; Zhang X; Chen J; Medvedovic M; Goodman ZD; Sherman KE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):353-358. PubMed ID: 27898525
[TBL] [Abstract][Full Text] [Related]
5. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
[TBL] [Abstract][Full Text] [Related]
6. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
[TBL] [Abstract][Full Text] [Related]
7. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
[TBL] [Abstract][Full Text] [Related]
9. HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing.
Ruggiero T; Burdino E; Calcagno A; Bonora S; Boglione L; Di Perri G; Ghisetti V
Infection; 2016 Dec; 44(6):789-792. PubMed ID: 27522673
[TBL] [Abstract][Full Text] [Related]
10. Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection.
Lieveld FI; Swaans N; Newsum AM; Ho CK; Schinkel J; Molenkamp R; van der Meer JT; Arends JE; Hoepelman AI; Wensing AM; Siersema PD; van Erpecum KJ; Boland GJ
Ann Hepatol; 2016; 15(5):696-704. PubMed ID: 27493108
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
[TBL] [Abstract][Full Text] [Related]
12. Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT
PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
15. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.
Bartolini B; Giombini E; Zaccaro P; Selleri M; Rozera G; Abbate I; Comandini UV; Ippolito G; Solmone M; Capobianchi MR
Virus Res; 2013 Nov; 177(2):205-8. PubMed ID: 23954579
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
17. Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.
Abdel-Hameed EA; Rouster SD; Boyce CL; Zhang X; Biesiada J; Medvedovic M; Sherman KE
Dig Dis Sci; 2018 Mar; 63(3):645-652. PubMed ID: 29330726
[TBL] [Abstract][Full Text] [Related]
18. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
19. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
